Equasens (FR:EQS)
:EQS
Want to see FR:EQS full AI Analyst Report?
EQS Stock Chart & Stats
€41.90
€0.30(0.74%)
At close: 4:00 PM EST
€41.90
€0.30(0.74%)
Day’s Range― - ―
52-Week Range€33.70 - €53.70
Previous CloseN/A
Volume720.00
Average Volume (3M)10.91K
Market Cap
€579.04M
Enterprise Value€558.22M
Total Cash (Recent Filing)€87.10M
Total Debt (Recent Filing)€53.80M
Price to Earnings (P/E)15.0
Beta0.72
Next Earnings
Sep 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.85%
Share Statistics
EPS (TTM)2.59
Shares Outstanding15,174,125
10 Day Avg. Volume9,833
30 Day Avg. Volume10,915
Financial Highlights & Ratios
PEG Ratio2.33
Price to Book (P/B)2.60
Price to Sales (P/S)2.89
P/FCF Ratio14.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.04
Revenue Forecast (FY)€260.90M
Bulls Say, Bears Say
Bulls Say
Client AcquisitionItaly is a bright spot with organic growth of 13.3% and +50 new client wins, showing that investments in the sales force are paying off.
Market MomentumOrganic growth should accelerate, and margins expand, benefiting from improving market momentum and product launches.
Organic GrowthEquasens had a strong Q1 with 5.9% organic growth, which should help the company regain some of the lost confidence from the investment community.
Bears Say
UndervaluationEquasens is materially undervalued given that its momentum is set to improve in 2025, with a potential for re-rating driven by improved end-customer health, new product launches, regulatory tailwinds, and easier comparison basis.
Equasens News
EQS FAQ
What was Equasens’s price range in the past 12 months?
Equasens lowest stock price was €33.70 and its highest was €53.70 in the past 12 months.
What is Equasens’s market cap?
Equasens’s market cap is €579.04M.
When is Equasens’s upcoming earnings report date?
Equasens’s upcoming earnings report date is Sep 28, 2026 which is in 111 days.
How were Equasens’s earnings last quarter?
Equasens released its earnings results on Mar 30, 2026. The company reported €1.468 earnings per share for the quarter, beating the consensus estimate of N/A by €1.468.
Is Equasens overvalued?
According to Wall Street analysts Equasens’s price is currently Overvalued.
Does Equasens pay dividends?
Equasens pays a Annually dividend of €1.4 which represents an annual dividend yield of 2.85%. See more information on Equasens dividends here
What is Equasens’s EPS estimate?
Equasens’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Equasens have?
Equasens has 15,174,125 shares outstanding.
What happened to Equasens’s price movement after its last earnings report?
Equasens reported an EPS of €1.468 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 13.889%.
Which hedge fund is a major shareholder of Equasens?
Currently, no hedge funds are holding shares in FR:EQS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Equasens
Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.
Technical Analysis
Cegedim
―
Eurobio-Scientific SA
―
Median Technologies
―
Biosynex SA
―
ABL Diagnostics SA
―
Options Prices
Currently, No data available
---